Palo Alto Investors Acquires Stake in Compass Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy CMPX?
Source: Fool
- New Investment Activity: Palo Alto Investors LP initiated a new position in Compass Therapeutics by purchasing 2,532,419 shares in Q4 2025, amounting to an investment of $13.60 million, indicating strong confidence in the biotech firm.
- Position Analysis: This investment represents 1.89% of Palo Alto Investors LP's assets under management, highlighting the firm's significant interest in Compass, which may influence future investment strategies.
- Stock Performance: As of February 17, 2026, Compass Therapeutics shares were priced at $6.39, reflecting a remarkable 101.58% increase over the past year, significantly outperforming the S&P 500 by 77.14 percentage points, showcasing market recognition of its growth potential.
- Company Overview: Compass Therapeutics focuses on developing antibody therapeutics targeting cancer and tumor vascularization, and as it advances through clinical trials, successful product approvals and partnerships are expected to generate substantial revenue potential for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.420
Low
8.00
Averages
12.67
High
24.00
Current: 5.420
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Therapeutics Reports Q4 and Full Year 2025 Financial Results
- Financial Performance: Compass Therapeutics reported a Q4 GAAP EPS of -$0.09, with a net loss of $66.5 million for the year ending December 31, 2025, compared to $49.4 million in 2024, indicating ongoing challenges in profitability.
- R&D Expense Increase: R&D expenses rose to $56.0 million in 2025 from $42.3 million in 2024, a 32% increase primarily driven by $7.7 million in manufacturing costs related to tovecimig and $5.9 million for CTX-10726, reflecting the company's commitment to drug development.
- Administrative Cost Rise: General and administrative expenses increased to $16.9 million in 2025 from $15.1 million in 2024, a 12% rise, largely due to pre-commercialization expenses of $0.7 million and advisory fees of $0.5 million, indicating increased spending in market readiness.
- Cash Position: As of December 31, 2025, Compass had $209 million in cash and marketable securities, up from $127 million in 2024, with an expected cash runway into 2028, despite using $49 million in net cash for operating activities, offset by $129 million in net proceeds from a public offering.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Palo Alto Investors Acquires Stake in Compass Therapeutics
- New Investment Activity: Palo Alto Investors LP initiated a new position in Compass Therapeutics by purchasing 2,532,419 shares in Q4 2025, amounting to an investment of $13.60 million, indicating strong confidence in the biotech firm.
- Position Analysis: This investment represents 1.89% of Palo Alto Investors LP's assets under management, highlighting the firm's significant interest in Compass, which may influence future investment strategies.
- Stock Performance: As of February 17, 2026, Compass Therapeutics shares were priced at $6.39, reflecting a remarkable 101.58% increase over the past year, significantly outperforming the S&P 500 by 77.14 percentage points, showcasing market recognition of its growth potential.
- Company Overview: Compass Therapeutics focuses on developing antibody therapeutics targeting cancer and tumor vascularization, and as it advances through clinical trials, successful product approvals and partnerships are expected to generate substantial revenue potential for the company.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Compass Therapeutics Initiates Coverage with $1.46B Peak Sales Potential for Tovecimig
- Significant Market Opportunity: William Blair initiates coverage of Compass Therapeutics, highlighting the potential of its lead drug tovecimig in second-line biliary tract cancer treatment, with an estimated 15,000 eligible patients annually in the U.S., positioning this market opportunity on par with first-line metastatic melanoma.
- Optimistic Sales Forecast: Analysts project peak worldwide sales of $1.46 billion for tovecimig in biliary tract cancer, resulting in a net present value of $9.84 per share for Compass, indicating strong investment potential.
- Potential New Standard of Care: The efficacy data for tovecimig is expected to exceed the benchmarks set by FOLFOX in the ABC-06 trial, potentially establishing it as the new standard of care in second-line biliary tract cancer, thereby enhancing the company's competitive edge in oncology.
- Broader Indication Prospects: Analysts also note proof of concept for DLL4xVEGF bispecifics in other indications such as ovarian and colorectal cancers, further bolstering Compass's long-term growth prospects.
See More
Compass Therapeutics Reports Q4 and Full Year 2025 Financial Results
- Financial Performance: Compass Therapeutics reported a Q4 GAAP EPS of -$0.09, with a net loss of $66.5 million for the year ending December 31, 2025, compared to $49.4 million in 2024, indicating ongoing challenges in profitability.
- R&D Expense Increase: R&D expenses rose to $56.0 million in 2025 from $42.3 million in 2024, a 32% increase primarily driven by $7.7 million in manufacturing costs related to tovecimig and $5.9 million for CTX-10726, reflecting the company's commitment to drug development.
- Administrative Cost Rise: General and administrative expenses increased to $16.9 million in 2025 from $15.1 million in 2024, a 12% rise, largely due to pre-commercialization expenses of $0.7 million and advisory fees of $0.5 million, indicating increased spending in market readiness.
- Cash Position: As of December 31, 2025, Compass had $209 million in cash and marketable securities, up from $127 million in 2024, with an expected cash runway into 2028, despite using $49 million in net cash for operating activities, offset by $129 million in net proceeds from a public offering.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Palo Alto Investors Acquires Stake in Compass Therapeutics
- New Investment Activity: Palo Alto Investors LP initiated a new position in Compass Therapeutics by purchasing 2,532,419 shares in Q4 2025, amounting to an investment of $13.60 million, indicating strong confidence in the biotech firm.
- Position Analysis: This investment represents 1.89% of Palo Alto Investors LP's assets under management, highlighting the firm's significant interest in Compass, which may influence future investment strategies.
- Stock Performance: As of February 17, 2026, Compass Therapeutics shares were priced at $6.39, reflecting a remarkable 101.58% increase over the past year, significantly outperforming the S&P 500 by 77.14 percentage points, showcasing market recognition of its growth potential.
- Company Overview: Compass Therapeutics focuses on developing antibody therapeutics targeting cancer and tumor vascularization, and as it advances through clinical trials, successful product approvals and partnerships are expected to generate substantial revenue potential for the company.
See More
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Compass Therapeutics Initiates Coverage with $1.46B Peak Sales Potential for Tovecimig
- Significant Market Opportunity: William Blair initiates coverage of Compass Therapeutics, highlighting the potential of its lead drug tovecimig in second-line biliary tract cancer treatment, with an estimated 15,000 eligible patients annually in the U.S., positioning this market opportunity on par with first-line metastatic melanoma.
- Optimistic Sales Forecast: Analysts project peak worldwide sales of $1.46 billion for tovecimig in biliary tract cancer, resulting in a net present value of $9.84 per share for Compass, indicating strong investment potential.
- Potential New Standard of Care: The efficacy data for tovecimig is expected to exceed the benchmarks set by FOLFOX in the ABC-06 trial, potentially establishing it as the new standard of care in second-line biliary tract cancer, thereby enhancing the company's competitive edge in oncology.
- Broader Indication Prospects: Analysts also note proof of concept for DLL4xVEGF bispecifics in other indications such as ovarian and colorectal cancers, further bolstering Compass's long-term growth prospects.
See More
